IP Library Granted Patent US 12674795
Granted Patent B2
US 12674795 · App. 17/607,669 · Granted Jul 7, 2026

Method for peritoneal metastatic cell detection and isolation thereof

Inventors: Sze Tsai Alice Wong (Hong Kong, CN); Ho Cheung Anderson Shum (Hong Kong, CN); Shanshan Li (Shenzhen, CN); Ka Man Ip (Hong Kong, CN); Kei Shuen Tang (Hong Kong, CN)
Assignee: VERSITECH LIMITED
G01N33/5011G01N33/5753G01N33/57535G01N33/57545G01N33/5755G01N33/57555
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12674795
App. No.
17/607,669
Granted
Jul 7, 2026
Kind
B2
Abstract

Provided herein is a method for the detection and isolation of metastatic cells from a sample obtained from a subject. Also provided is a device comprising a microchip for use in the method. Also provided is a method of isolating the metastatic cells for culture and characterization. Provided herein is a kit for the method therein.

Claims (13)

1 . A method for detecting peritoneal metastatic cells in a sample obtained from a subject comprising: (a) flowing the sample using a microfluidic device at an effective wall shear stress, wherein a channel bottom of the microfluidic device is coated with P-selectin, wherein the effective wall shear stress is about 0.1-0.15 dyne/cm 2 , and contacting peritoneal metastatic cells and peritoneal non-metastatic cells in the sample with P-selectin such that the peritoneal non-metastatic cells are all washed away, and the peritoneal metastatic cells selectively bind to the P-selectin; and (b) detecting selective binding of the peritoneal metastatic cells to the P-selectin.

2 . The method of claim 1 , wherein the peritoneal metastatic cells are from gastrointestinal cancer or gynecological cancer.

3 . The method of claim 2 , wherein the gynecological cancer is ovarian cancer, uterine cancer, cervical cancer or vaginal cancer.

4 . The method of claim 1 , wherein the gastrointestinal cancer is liver cancer, colon cancer, prostate cancer, bladder cancer and rectal cancer.

5 . The method of claim 1 , further comprising a step of isolating the peritoneal metastatic cells.

6 . The method of claim 1 , further comprising a step of culturing the peritoneal metastatic cells.

7 . The method of claim 1 , further comprising a step of characterizing the peritoneal metastatic cells.

8 . The method of claim 1 , wherein the effective wall shear stress is about 0.1 dyne/cm 2 .

9 . The method of claim 1 . wherein the microfluidic device is a microfluidic chip.

10 . The method of claim 1 , wherein the peritoneal metastatic cells are detected by a label.

11 . The method of claim 1 , wherein the P-selectin is a P-selectin-Fc recombinant protein.

12 . The method of claim 1 , wherein the channel bottom is prepared by incubating with 1 μg mL −1 selectin-Fc recombinant protein in PBS at 4° C. overnight.

13 . The method of claim 12 , further comprising a step of EDTA detachment, wherein the step of EDTA detachment comprises introducing the sample in a binding buffer into the channel bottom coated with P-selectin recombinant protein at a shear stress of 0.1 dynes/cm 2 for 1 min followed by perfusion with PBS for 1 min at the shear stress of 0.1 dynes/cm 2 .